• WKN: UB0BL6
  • ISIN: CH0024899483
  • Land: Schweiz

Nachricht vom 08.06.2021 | 09:00

UBS AG: Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

UBS AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act]
08.06.2021 / 09:00
Dissemination of a Post-admission Duties announcement according to Article 50 Para. 1, No. 2 WpHG transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

UBS AG acting through its London Branch has issued a triple-tranche USD 3.0 billion senior benchmark transaction consisting of a 5-year USD 1.0 billion fixed rate note (ISIN: US902674YH70) maturing on 1 June 2026; a 2-year USD 1.0 billion fixed rate note (ISIN: US902674YF15) maturing on 1 June 2023; and a 2-year USD 1.0 billion floating rate note (ISIN: US902674YG97) maturing on 1 June 2023). Settlement date for all tranches is 1 June 2021.

08.06.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021